LABORATOIRES THEA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
58
Trial Phases
5 Phases
Drug Approvals
45
Drug Approvals
MONOPROST 50 MICROGRAMOS/ML COLIRIO EN SOLUCION EN ENVASE UNIDOSIS
- Approval Date
- Jul 14, 2025
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease
- Conditions
- Dry Eye Disease (DED)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 30
- Registration Number
- NCT07007702
- Locations
- 🇦🇹
Universitätsklinik für Klinische Pharmakologie, Allgemeines Krankenhaus Wien, Wien, Austria
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
- Conditions
- Dry Eye Disease (DED)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 30
- Registration Number
- NCT06903741
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
- Conditions
- Leber Congenital Amaurosis 10Sensation DisordersEye DiseasesBlindnessEye Disorders CongenitalLeber Congenital AmaurosisNeurological ManifestationsEye Diseases, HereditaryVision DisorderRetinal Disease
- Interventions
- Other: Placebo IVT
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 32
- Registration Number
- NCT06891443
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent (UZ), Gent, Belgium
🇩🇪Justus-Liebig Universität - Department of Ophthalmology, Gießen, Germany
🇩🇪University of Tuebingen - Inst. for Ophthalmic Research, Tuebingen, Germany
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
- Conditions
- Retinitis Pigmentosa (RP)Usher Syndrome Type 2Deaf BlindRetinal DiseaseEye Diseases, HereditaryEye Disorders CongenitalVision Disorders
- Interventions
- Other: No intervention, will not receive any active study intervention
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 81
- Registration Number
- NCT06627179
- Locations
- 🇺🇸
Massachusetts Eye and Ear, Boston, Massachusetts, United States
🇺🇸University of Michigan- Kellogg Eye Center, Ann Arbor, Michigan, United States
🇺🇸Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 126
- Registration Number
- NCT06394973
- Locations
- 🇺🇸
Arizona Advanced Eye Research Institute, Glendale, Arizona, United States
🇺🇸Global Research Management, Inc., Glendale, California, United States
🇺🇸United Medical Research Institute, Inglewood, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Emerging Therapies Offer Hope for Usher Syndrome Patients
The Usher Syndrome market is poised for growth with emerging therapies addressing the root cause of the disease, offering alternatives to supportive care.